Your selection
NoneFilter by content type
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
July 23, 2021 - … Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s … International Conference Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s … will include several presentations highlighting data on ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution, …
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
June 7, 2021 - … to help patients with Alzheimer’s disease access ADUHELM™ Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™ June 7, 2021 News Release General Programs now … and Drug Administration’s (FDA) accelerated approval of ADUHELM TM (aducanumab-avwa) as the first and only …
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
March 16, 2022 - … Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of … for More Than Two Years Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of … More Than Two Years March 16, 2022 News Release General ADUHELM continued to reduce two key Alzheimer’s disease …
Update on the Phase 4 Confirmatory Study of ADUHELM®
December 16, 2021 - … Update on the Phase 4 Confirmatory Study of ADUHELM® Update on the Phase 4 Confirmatory Study of ADUHELM® December 16, 2021 News Release General CAMBRIDGE, … of the Phase 4 post-marketing confirmatory study of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for …
Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
December 22, 2021 - … aducanumab to patients in Japan expeditiously. About ADUHELM ® (aducanumab-avwa) injection 100 mg/mL solution for intravenous use In the United States, ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive …
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease
December 20, 2021 - … Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early … Alzheimer’s Disease Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early … it will reduce the wholesale acquisition cost (WAC) of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for …
Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease
April 7, 2022 - … effectively denies all Medicare beneficiaries access to ADUHELM ® (aducanumab-avwa), the first and only FDA-approved … continuity of care for Medicare beneficiaries already on ADUHELM. Biogen is carefully considering its options and … evaluates the business impact of this decision. About ADUHELM ® (aducanumab-avwa) injection 100 mg/mL for …
Biogen’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
January 11, 2022 - … denies nearly all Medicare beneficiaries from accessing ADUHELM® (aducanumab-avwa) 100 mg/mL injection for … approval was supported by clinical data showing that ADUHELM impacted the underlying pathology of Alzheimer’s … screening for its post-marketing confirmatory study for ADUHELM® (aducanumab-avwa) in May 2022, with a primary …
Update on Regulatory Submission for Aducanumab in the European Union
December 17, 2021 - … Drug Administration (FDA) granted accelerated approval for ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for … the disease by reducing amyloid beta plaques in the brain. ADUHELM is also approved in the United Arab Emirates (UAE). About ADUHELM ® (aducanumab-avwa) injection 100 mg/mL solution for …
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
November 11, 2021 - … New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in … Disease New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in … 11, 2021 News Release General In a pre-specified analysis, ADUHELM significantly lowered plasma p-tau181, a biomarker of …
